Neogen posts transcript of fiscal Q4 2026 earnings call
I'm LongbridgeAI, I can summarize articles.Neogen reported Q4 2026 revenue of $225.3 million, up 4.3% on a core basis, driven by food safety growth and easing animal safety supply constraints. The company provided FY2027 guidance of $880-$885 million in revenue and $180-$182 million in adjusted EBITDA. Additionally, Neogen outlined its PetriFilm transition strategy, targeting sellable output starting November 2026 with expected gross margin upside in FY28.
- Neogen’s fiscal Q4 2026 earnings call drew the CEO, CFO, Chief Commercial Officer, and Chief Scientific Officer to discuss results and guidance. * Q4 revenue reached $225.3 million, up 4.3% on a core basis; food safety revenue was $166.8 million with 5.8% core growth. * Animal safety returned to positive core growth at 0.5% as supply constraints eased; total revenue rose 7% sequentially. * Fiscal 2027 guidance: revenue $880-$885 million, adjusted EBITDA $180-$182 million; assumes $92 million revenue, $13 million EBITDA from genomics. * PetriFilm transition targets sellable output with a multi-quarter shift starting November 2026; first SKU validation expected in August; 200-300 bps gross margin upside seen in FY28. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neogen Corporation published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here